- EN
- JP
Metagen Therapeutics, Inc.
Bringing innovative medicine and pharmaceuticals to life
through cutting-edge microbiome science
News
-
【Media Coverage】CSO Terauchi interviewed by Microbe Musings on Today’s Microbiome Therapeutics Industry in Asia
August 13, 2023- “Nurturing the Microbiome Therapeutics Industry in Asia,” a blog focusing on the latest news […] -
【Press Release】Metagen Therapeutics Presents Latest Research at Microbiome Movement, the World’s Largest Microbiome Conference, and Other Major Conferences
Showcasing our progress of “gut microbiome therapy” research in Japan Yamagata, Japan, July 4, 2023–Metagen Th […] -
【Press Release】Metagen Therapeutics Completes Series A Financing Raising a Total of 1.7 Billion Yen
Yamagata, Japan, June 15, 2023-Metagen Therapeutics (President & CEO: Taku Nakahara), a company focusing o […] -
【Press Release】Metagen Therapeutics Raises JPY 1.1B in Initial Closing of Series A
Yamagata, Japan – Metagen Therapeutics (President and CEO: Taku Nakahara, PhD; Headquarters: Yamagata, Japan; […] -
【Press Release】Antibiotic Fecal Microbiota Transplantation for Ulcerative Colitis Patients Approved Under Japan’s Advanced Medical Care Program
January 4, 2023 JAPAN – Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai) and Metagen Therapeutic […]
Medical Services・Pipeline/Platform
The human microbiome is comprised of bacterial flora found throughout the human body, including in the intestines, skin, and oral cavity. Intestinal microbiome in particular, has a complex and dynamic population of microorganisms. In recent years, research on the intestinal flora has made significant progress and its symbiotic relationship with various diseases such as cancer, ulcerative colitis, Parkinson’s disease, and allergies, has become clear.
FMT and its research has been shown to be a safe and efficacious treatment around the world, and microbiome drug discovery is being actively carried out.
Founders

Chief Executive Officer
Taku Nakahara Ph.D., MBA

Chief Medical Officer
Dai Ishikawa MD, Ph.D.
Associate Professor
Juntendo University,
Department of Gastroenterology,
Faculty of Medicine


Senior Scientific Advisor
Shinji Fukuda MD, Ph.D.
Project Professor
Keio University,
Institute for Advanced Biosciences


Senior Scientific Advisor
Takuji Yamada Ph.D.
Associate Professor
Tokyo Institute of Technology,
School of Life Science and Technology

腸内細菌療法
メタジェンセラピューティクスはCMO石川が順天堂大学で研究してきた腸内細菌療法の普及を目指します。
Partners



Company
Metagen Therapeutics, Inc. (MGTx)
January 2020
Drug discovery and medical services using microbiome science
President & CEO Taku Nakahara
Director, CMO Dai Ishikawa
Director, CSO Jun Terauchi
Non-Executive Director Tomohiro Anzai
Non-Executive Director Taira Kobayashi
Non-Executive Director Jun Hayashi
Senior Scientific Advisor Shinji Fukuda
Senior Scientific Advisor Takuji Yamada
246-2 Mizukami, Kakuganji, Tsuruoka-city, Yamagata 997-0052 Japan
Toranomon Hills Business Tower 15F
1-17-1 Toranomon, Minato-ku, Tokyo 105-6415 Japan